Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
99.18
-0.68 (-0.68%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
95
96
Next >
Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients
August 18, 2023
Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible
Via
Benzinga
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
August 18, 2023
From
Merck & Co., Inc.
Via
Business Wire
Federal Court Rules To Prohibit Access To Abortion Pill: Supreme Court To Weigh In
August 16, 2023
The 5th Circuit Court of Appeals ruled Wednesday to prohibit access to mifepristone, the drug known as the abortion pill, in a case filed against the Food and Drug Administration.
Via
Benzinga
Check Out What Whales Are Doing With MRK
August 14, 2023
Via
Benzinga
Is Merck Stock a Buy Now?
August 10, 2023
There's a lot to like about this blue-chip company, but it has its problems, too.
Via
The Motley Fool
Merck & Co Unusual Options Activity
August 08, 2023
Via
Benzinga
This Is What Whales Are Betting On Merck & Co
August 04, 2023
Via
Benzinga
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
August 14, 2023
These undervalued penny stocks each provide big upside potential, while trading with relatively high margins of safety.
Via
InvestorPlace
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare
August 11, 2023
Healthcare stocks are starting to shine in 2023 after bottoming out and MRK stock is particularly appealing. Here's why.
Via
InvestorPlace
Pharma ETFs in Focus Post Q2 Earnings
August 11, 2023
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.
Via
Talk Markets
Topics
ETFs
The 3 Best ESG Stocks to Buy in August
August 10, 2023
Although doing right would seem to come at a cost to shareholder profit potential, these best ESG stocks to buy prove otherwise.
Via
InvestorPlace
Peering Into Merck & Co's Recent Short Interest
August 03, 2023
Via
Benzinga
Expert Ratings for Merck & Co
August 02, 2023
Via
Benzinga
Merck (MRK) Q2 2023 Earnings Call Transcript
August 01, 2023
MRK earnings call for the period ending June 30, 2023.
Via
The Motley Fool
My Oh My, Merck Stock Is a No-Brainer Income Stock to Buy
August 10, 2023
The pharmaceutical company has outperformed the market over the past five years.
Via
The Motley Fool
The 3 Best Healthcare Stocks to Buy in August
August 09, 2023
Healthcare is always the answer in the face of volatility. Here are the three best healthcare stocks to buy in the sector.
Via
InvestorPlace
Mirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit
August 09, 2023
The company announced updates in cancer, a quarterly beat, a $300 million deal and its CEO departure.
Via
Investor's Business Daily
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
August 09, 2023
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the...
Via
Benzinga
Merck Is Driving Ginkgo Bioworks Stock Higher Monday: What's Going On?
August 07, 2023
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher Monday after the company announced a collaboration with Merck & Company Inc (NYSE: MRK) focused on
Via
Benzinga
Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling
August 07, 2023
The Nasdaq 100 closed lower on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
August 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
Is It Time to Buy the Dow Jones' 3 Worst-Performing July Stocks?
August 03, 2023
These three Dow stocks had a tough go of it in July; is the pain over, or are investors in for more hurt in the months ahead?
Via
The Motley Fool
Rising Dividend Make Zoetis a Doggone Winner
August 03, 2023
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis.
Via
MarketBeat
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
August 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Fear & Greed Index Moves To 'Greed' Zone After S&P 500 Settles Lower
August 02, 2023
U.S. stocks closed mixed on Tuesday, as investors digested recent earnings reports and a fresh batch of economic data.
Via
Benzinga
Exact Sciences, A Cathie Wood Darling, Just Reported A Sixth Big Sales Quarter
August 01, 2023
The company is a leader in using diagnostics to screen for early cancer cases.
Via
Investor's Business Daily
Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives
August 01, 2023
(Tuesday market open) The new month starts with stocks tinted red, but this week’s main events are just getting underway. A rise in Treasury yields might have investors nervous early Tuesday as the...
Via
Benzinga
The 2 Dow Stocks Everyone's Watching Tuesday Morning
August 01, 2023
Find out the latest on these blue chip companies.
Via
The Motley Fool
Merck Swings Into Q2 Loss On Prometheus Biosciences Acquisition Charge, But Raises FY23 Revenue Outlook
August 01, 2023
Merck & Co Inc's (NYSE: MRK) Q2 sales reached $15.04 billion, up 3% Y/Y, beating the consensus of $14.39 billion.
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
95
96
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.